Clinical Trial Update: A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated intranasal esketamine plus an oral antidepressant for relapse prevention in adults with treatment-resistant depression; results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Treatment-resistant Depression

Drugs mentioned

• Oral antidepressant (unspecified)
• Spravato (esketamine) (esketamine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Depressive Disorder, Treatment-Resistant | Phase 3 | Status: COMPLETED | Results posted: 2019-05-21